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Biopsies of involved and uninvolved skin frOlTl psoriatic 
patients and of normal skin were stained immunocyto-
chemically with monoclonal antibodies against urokinase-
type (u-PA) and tissue-type (t-PA) plasminogen activator 
using a multilayer peroxidase technique. Epidermis from 
psoriatic resions showed focal staining for u-PA in and 
between the basal keratinocytes in the suprapapillary epi-
dermal areas, while t-PA was found,in the superficial ker-
atinizing cells, including both stratum spinosum and the 
P lasminogen activators are serine proteases which can convert the extracellular zy mogen plasminogen into the active protease, plasmin. Plasmin has a relatively broad trypsin-like specificity and is able to degrade most pro-teins. Secretion of plasminogen activators may by this 
cascade react ion lead to localized extracelJular proteolysis [1-4]. 
Two types of plasminogen activators, tiss ue-type (t-PA) with M .. 
- 70,000 and urokinase-type (u-PA) with Mr - 50,000 have been 
found in mammals. They are products of different genes located 
on chrom osomes 8 and 10, respectively [5-7]. They seem to take 
part in different biologic processes, t-PA being a key enzyme in 
thrombo lysis and u-PA, among other functions, being implicated 
in tissue degradation in both normal and pathologic conditions, 
including cancer (for reviews, see f1,4]). 
Plasminogen activator activity has been demonstrated in the 
sca les and epidermis of psoriatic skin [8-15]. In a previous im-
munochemical study on psoriatic scale extracts [1 6], we found 
that t-PA, but not u-PA , cou ld be detected. The aim of the present 
study was to investi gate the immunocytochemical localization of 
the plasminogen activators in psoriatic sk in . 
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Abbreviations: 
BSA: bovine serum albu m in 
ELIS A: enzyme-linkcd immunosorbent assay 
PBS: phosphate-buffered sa line 
TBS: 0.05 M Tris-HCI with 0.15 M N aCI, pH 7.4 
t-PA: tissue-type plasminogen activator 
u-PA: urokinase-type plasmi nogcn activator 
parakeratotic layer. No stainin g of keratinocytes was ob-
served in uninvolved and normal skin. The specificity of 
the staining was supported by the finding that 3 different 
monoclonal antibodies and polyclonal antibodies against 
each of the plas minogen activators gave identical staining, 
while monoclonal antibodies of irrelevant speciflcity gave 
no staining. The present findings suggest abnormalities in 
the regulation of both types of plasminogen activators in 
psoriatic epidermis . J Irlll esl Dermatol 88:28-32, 1987 
MA TERIALS AND METHODS 
Materials The folJowin g m aterials were obtained from the 
indicated sources: protein A-Sepharose and cyanogen bromide-
activated Sepharose (Pharmacia Fine Chemicals, Uppsala, Swe-
den); swine antirabbit immunoglobulin, rabbit peroxidase-
antiperoxidase complexes, rabbit antimouse immunoglobulin, 
and peroxidase-conjugated rabbit antimouse immunoglobulin 
(Dakopatts, Copenhagen); goa t antibodies specific for mOllse im-
munoglobulin classes and IgG subclasses (Meloy, Springfi eld, 
Virginia); biotinyl-N-hydroxys uccinimide (Sigma Chemica l Co. , 
St. Loui s, Missouri); Immunoplate I (Nunc, Roskilde, Denmark); 
bovinc serum albumin (Behring, Marburg, F.RG.); and per-
oxidase-conjugated avidin (Kem-En-Tec, Hellerup, Denmark). 
All other materials were those described previously [16-19]. 
Tissue and Tissue Treatment Procedures Biopsies from 11 
psoriatic patients attending the Department of Dermatology of 
the Finsen Institute and frol11 3 health y adult volunteers were 
studied. From each patient, 4-mIl1 punch biopsies were obta ined 
from both involved and uninvolved skin, taken 0.5-1.0 CI11 apart. 
The biopsies were immediately frozen either in isopentane on dry 
ice (psoriasis patients) or in liquid nitrogen (healthy subjects) and 
then stored at -70°C. Five-micron seria l cryostat sections were 
applied to chrome gala tine (1 % gelatine and 0.05% KCr 
(SO,,)z·]2 H20)-coated glass slides and stored at -70°C until 
stainin g. Prior to staining, the sections were thawed at 4°C in 
0.1 M phosphate buffer (pH 7.4) containing 4% paraformalde-
hydc for 1 h. 
Antibodies Monoclonal mouse antibodies against human t-pA 
and u-P A (anti-t-PA clones 1, 2, and 3, anti-u-PA clones 2, 6, and 
12) were derived from 6 different hybrid izations. T he derivation 
of anti-t-PA clone 1 and anti-u-PA clone 2 have been described 
previously [16,18-20] . The other 4 antibodies were derived by 
the use of identical procedures . All 6 antibodies are further char-
acterized in the present study (see below) . T hree monoclonal 
antibodies with irrelevant specificity (denominated 1-1ATR 1-18, 
HYT 6, and HAT 3) were kind ly provided by Ralf Agger, T u-
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berculosis Department, Statens Seruminstitut, Copenhagen. HATR 
1-18 is directed against a 30-kD component from rabbit tes tis , 
whereas HYT 6 and HAT 3 are directed aga inst different com-
ponents of NJy cobllcter;J.l1I1 tllbercu los;s (Ralf Agger, personal com-
munication) . Another m onoclonal an tibody with irrelevant spec-
Ificity, anti-2,4,6-trinitropheny l (anti-T NP) (Hy 2.15) [21] was 
the kind gift of Georges Kohler, Basel In stitute of Immunology, 
SWitzerl and. All the monoclonal antibodies w ere produced in cell 
cultu re and purifi ed on protein A-Sepharose prior to use [1 8]. 
They were all of the IgG \ subclass, as determined by immuno-
diffusion against goat antibodies specifi c for mouse im muno-
globulin classes and subclasses . 
Polyclonal rabbit antibodies against human t-PA and u-PA 
Were those described by Kristensen et al [1 7]. 
Biotin conju ga tion of monoclonal antibod ies was perfo rm ed 
by th e method of Guesdon et al [22] with so me modifications: 1 
1111 of 0.1 M NaH CO] containing approx imately 1 mg of antibody 
Was mi xed with 600 nmol per m g antibody of bio tinyl-N-
hydro xysuccinimide. T he mix ture was in cubated at room tem-
perature fo r '1 h and then dialyzed overnight at 4°C aga inst phos-
phate-buffered sa line (PBS). 
In order to reduce backg round sta ining, 1. 8 ml of the co m-
nle.rcial rabbit anti mouse immunoglobulin preparation was af-
finIty-purifi ed on a 2-ml Sepharose column coupled with 8 m g 
monoclonal anti-TNP IgG \. The column was washed with 5 ml 
ofTris-HC l, pH 8. 1, and 2 ml Tris-HC l, pH 8. 1, 1 M NaCl, and 
eluted with 9 ml of 0 .1 M glycine, pH 2.5, 0.5 M NaC I. The 
eluate was neutralized by addition of 0 .1 vol of 1 M Tris-HC I, 
pH 9.0. This resulted in 3 ml at a concentrati on of 243 ILg /nll . 
Plastninogen Activator Assay To tes t the specificity of the 9 
monoclonal ant ibodies used for the immunocytochemical local-
IZa tion of th e plasminogen activators, th eir effect on the enzy matic 
~CtlVlty of the 2 plasminogen act i va~ors was tested with the '.251_ 
~eled fibnn plate assay [23], 111.0dlfied as desCrIbed [19]. Fifty 
microliters of 0.1 M Tris-HCl, pH 8.1, 0.1 % Triton X-I00 con-
taining monoclonal antibody at a concentration of 1 0 ILg/ml , and 
prO-t-PA or pro-u-PA at a concentration of 500 pg/ ml was prein-
cuba ted for 1 h at 37°C, and added to assay well s containing 0.5 
111.1 of 0.1 M Tris-H C I, pH 8.1,0.1% Triton X -I 00, 0.25% gel-
~tl\~e, 1 ILg hum an Gl u-plasminogen, and 8 ng plasmin. Incu-
~tlon was carried out for 1 h at 37°C. Due to the presence of 
P as nlln , this assay allows the simultaneous determination ofplas-
I111l10gen activators and their proenzyme form s [1 9,24). 
~l1ZYtne-Linked Immunosorbent Assay (ELISA) The spec-
I IClty of th e antibodies was tested by ELISA. Immunoplates were 
CO~ted overnight at 37°C with 1 fLg / ml purified t-PA [16] , pro-
~O A [l 6], or plasminogen [25 ,26] in 0.1 M N azCO], pH 9.8, 
teiO ILl per well. T he plates were washed and the remaining pro-
( n-bll1dmg sites w ere blocked by II1cubatlon With 200 fLl 1 % 
bW/V) bovine serum albumin (BSA) in PBS for 30 min. Incu-
b atl?n Was performed with 25 ng/ml of the monoclonal anti-
odles . The plates were then washed and in cubated with per-
~~~dase-li n ked rabbit antimouse immunoglo bulins (Dakopatts P 
f, ) dIluted J : 800. Finally, peroxidase reaction was perfo rm ed 
Or 5 min w ith 0.1 % o-p henylened iamine, 0.0'1 'Yo 1-,"02 in 0.1 M ~~~ate-phosph ate buffer, pH 5.0. The reaction was stopped by 
ling 100 ILl 1 M H 2SO,1, and the absorbance was read at 490 ~m . In cubation with first and second antibody layers was per-
tormed at 37°C for 1 h. All other procedures we re done at room 
tllperatllre. All was hings between the incubations were per-
~rmed 4 times with PBS-Tween. All vo.lumes added to the wells 
~e 100 ILl unless otherwise stated . 
r, 0 eva luate w hether the monoclonal antibodies from the dif-
erent clones w ere directed against different epitopes on the plas-~llnogen activator m o lecul es, a 2-site ELISA [27] was used. Ex-
Stenl11enta l conditions were as described above, unless otherwise 
a ated. Iml11unoplates were coated with 2 fLg/ml of each of the 6 
1 ~JIPlasl11inogen activator monoclonal antibodies and blocked with 
o BSA III PBS. T hen, incubations were performed with pro-
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u-PA in concentrations of 1, 2, and 4 ng/ml o r t-PA in concen-
trations of 4, 8, an d 16 ng/ml followed by incubation w ith 1 
ILg/ml of biotin-conju gated anti-u-PA clone 2 or clone 6 (for u-
PAl , o r altern atively, bio tin-conju gated anti-t-PA clone 1 or clone 
2 (fo r t-PA) in PBS-Tween. Fina lly, the plates were incubated 
with peroxidase-conjuga ted avidin (158 ng/ml in PBS-Tween 
containing 1 % BSA) follow ed by peroxidase reaction, as above. 
Immunohistologic Staining Procedures Endogenous per-
oxidase ac tivity was blocked by incubating the tissue sections for 
10 min in methanol containing 0.03% hydrogen peroxide. The 
sections were washed with 0.05 M Tris-HCl , pH 7.4, 0.15 M 
NaC I, 1 % (w/v) Triton X-100 (TBS-Triton) , and then incubated 
success ivel y w ith (1) TBS (0.05 M Tris-HCI wi th 0. 15 M N aCI, 
pH 7.4) containin g 30% (v/v) norm al swine serum ; (2) mono-
clona l antibody diluted to a concentration of 10 ILg/m l in TBS 
containing 10% (v /v) norm al swine serum overnight at 4°C, fol-
lowed by 1 h at roo m temperatu re; (3) rabb it antimouse im-
munoglobulin , 10 ILg/ml; (4) swine antirabb it immunoglobulin 
:I : 50; and (5) rabbit peroxidase-anti perox idase complexes :I : 70. 
The polyclonal reagents were di lu ted in TBS containin g 10% 
(v /v ) normal swine serum and 5% (v /v) norm al human serum , 
except for the dilution of peroxidase-anti peroxidase com plexes, 
which was performed in TBS containing 10% (v /v) normal swine 
serum . All incubations w ere performed at room temperature in 
a humidified chamber for 30 min unless otherwise stated. Three 
10-min TBS-Triton washes fo llowed each incubation . A 10-min 
wash in 0.05 M Tris , pH 7.6, fo llowed the las t TBS-Triton wash. 
The peroxidase activity was demonstrated w ith diaminoben zi-
dine-H20 2 [28]. The sections were lightl y counterstained with 
hematoxylin . 
For stain ing with polyclonal rabbit anti plasminogen activato r 
antibodies as first antibody , the procedure was as described for 
th e m onoclonal antibodies, except that the m onoclonal antibody 
was repla ced with polyclonal rabbit antibodies (5ILg/ml) and the 
rabbit antimouse immunoglobulin la yer was omitted. 
Contro ls included (1) omission of either the first, second , third, 
o r fourth layer of antibody; and (2) replacement of the antiplas-
minogen activator antibodies with 3 different monoclonal anti-
bodies of irrelevant specificity. For the rabbit antibodies, contro l 
sections were perfo rmed by substitu ting the specific antibodies 
with either preimmune IgG o r immune rabbit antibod y prepa-
rations which had been absorbed by passage through Sepharose 
columns w ith the co rrespondin g anti gen [17] . 
Table I. Effect of Monoclonal Antibod ies on u-PA and t-PA 
E nzy m e Activity, M easured by the [125I'J Fibrin Plate Assay 
Monoclona l Antibod y 
Anti-L1-PA clone 2 
Anti-ll-PA clone 6 
Anti-L1-PA c10nc 12 
Anti-t-PA clone 1 
Anti-t-PA clone 2 
An ti-t-PA c10nc 3 
HAT 1-18 
HYT 6 
H AT 3 
Radioactivity Released 
(% of contro l) 
L1-PA t-PA 
7 88 
13 92 
4 96 
94 21 
95 50 
99 52 
11 2 93 
102 98 
101 104 
Urokinase-type (u-PA) or tiss lle-type (t-PA) plasminogen activators (500 pg/ ml) 
and monoclonal antibody (10 j.tg / ml) were "reincubated (or I h at 37°C in 0. 1 M 
Tris-HC I. pH 8. 1. 0.1 % Triton X- IOO. and 50 j.tl o( the l11ix[Ure was assayed in 
the 1' 251J fibrin plate assay. In this assay , the plasminogen activators COll vert plas-
minogen [0 plasmin w hich. ill turn, dl'gr:1dcs rh e iodinated fibrin . Results repre-
scntin g the 111C31l of 2 detcrmin:ltions arc ex pressed as :l percentage of the activity 
in well s wi th enzy me. but without alltibody. corresponding to approximately 12.000 
cpm (or u-PA and 16.000 cpm (or t-PA. Ibdioactivity (1'0 111 well s wi th out plas-
millogen acti va to r added (a pprox imatel y 2.000 cp m) has been subtracted. T he tota l 
ac ti vity in cach well was 48,000 Cp11l . T he released cpm (o r both enzy mes was 
lill c:lrly related to th e amount o( enzy me added up to app roximatel y 20.000 cpm. 
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Table II. E nzy m e-Linked Im munosorbent Assay for u-PA, 
t-PA, and P lasminogen with . Different M onoclonal Antibodies 
Solid Phase Antigen (absorbance) 
Monoclonal Antibody u-PA t-PA Plas minogen 
Anti-u-PA clone 2 0.21 0.00 0.02 
Anti-u-PA clone 6 1.38 0.00 0.02 
Anti-u-PA clone 12 0.87 0.00 0.01 
Anti-t-PA clone 1 0.00 0.95 0.01 
Anti-t-PA clone 2 0.01 1. 39 0.00 
Anti-t-PA clone 3 0.05 1.47 0.01 
HATR 1-18 0.05 0.01 0.02 
HYT6 0.05 0.01 0.02 
HAT 3 0.06 0.00 0.02 
Immunoplates we re coated with the indicated anti gens and incubated w ith the 
monoclo nal antibod ies, fo llowed b y peroxidase-conjugated rabb it antimouse im-
m Ull oglobulin . Peroxidase reaction was performed with o-phcnylcll cd iaminc and 
the absorba nce was measured at 490 nm . 
RESULTS 
Characterization of the Monoclonal Antibodies T he mono-
clona l an tibodies directed aga inst u-PA inhibited the ac tivity of 
u-PA stron gly at the concentrations used, as m easured by the 
[ 1251]_fibrin plate plasminogen activator assay (Table I) . These 
antibodies did not sig nificantly inhibit t-PA. T he m onoclonal 
antibodies directed against t-PA inhibited t-PA enzy m e activity, 
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Figure 1. Two-site ELI SA with monoclonal an tibodies and plasminogen 
activators. Immunoplates were coated with the indicated monoclonal an-
tibody, fo llowed by incubation with the correspond ing activator and the 
indicated biotin-conjugated monoclonal antibody . Binding of biotin-
conj ugated monoclonal antibody was demonstrated by perox idase-con-
juga ted avidin. A, Solid-phase IgG from anti-u-PA clone 2 (0, e), [rom 
anti-u-PA clone 6 (6, .... ), and fro lll anti-u-PA clone 12 (0, .). Bio-
tinylated IgG from an ti-u-PA clone 2 (0, 6, 0) and from anti-u-PA 
clone 6 (e, .... , . ). B, Solid-phase IgG from anti-t-PA clone 1 (0 , e ), 
from anti-t-PA clone 2 (6, .... ), and from anti-t-PA clone 3 (0, .). Biotin-
ylated IgG from anti-t-PA clone '1 (0, 6, 0 ) and [rom anti-t-PA clone 
2(e , .... , .). 
T H E JOU RNAL OF INVESTI GATIVE DERMATOLOGY 
Figure 2. Perox idase-anti perox idase staining of a psoriatic lesion with 
monoclona l atlti-t-PA from clonc 3 (A) and monoclona l anti-u- PA froll1 
clonc 12 (B). Note the t-PA immunoreacti vity in the stratum spinosurn 
and the parakeratot ic la yer, and the u-PA immunoreactivity in the basa l 
kerat inocytcs in the suprapapillary areas of epidermis (Bars = 127 !-'-111 ). 
altho ug h to a lesser exten t th an did the inhi bition of u-PA by 
anti-Ll-P A antibodi es. N one of the anti-t-PA an tibodies inhibited 
Ll-PA . T he 3 m o noclonal control antibod ies did no t inhibit either 
u-PA or t-PA (Table I) . 
E LlSAs were perfo rmed in w hich u-PA, t-PA , o r pl as min ogen 
were attached to the solid phase foll owed by in cubation w ith 
monoclonal antibodies. Bound m o noclonal antibody was then 
detected by in cubation w ith peroxid ase- conju gated rabbit anti-
mouse IgG. T he results presented in Table II show that all 3 
antibodies against t-PA reacted with t-PA but not w ith u-PA or 
pl asminogen, and that all 3 antibodies aga inst u-PA reacted w ith 
u-PA but not with t-PA or plas minogen . N o ne of the 3 antibodies 
o f ir re levant specifi city reacted w ith t-PA, u-PA, o r plasminogen. 
A 2-site E LIS A was used to assess whether the monoclonal 
antibodies to each of the activators were directed aga inst the sa me 
epito pes . O ne m o noclo nal antibody was bo und to the solid ph ase 
followed by in cubation with the corres pondin g activator. T hen, 
the wells were in cubated with biotin-conju ga ted mon oclo nal al1-
tibody and binding of thi s second antibod y w as determined by 
the peroxidase- conju ga ted avid in m ethod . A response dependent 
on the con centration of the res pective activators is considered to 
indi ca te that the so lid-phase antibo dy and the biotin-conju ga ted 
antibody are able to bind the antigen at the same time, w hich 
m ea ns that their epitopes are diffe rent. T he results in Fig lA shoW 
that IgG fro m anti-u-PA clone 2 could bind to u-PA together 
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Figure 3. Peroxidase-anti peroxidase sta inin g 
of a psoriatic les ion w ith monoclonal anti-t-
PA from clone 3 (A alld B), monoclonal anti-
u-PA li'om clone 12 (C alld D) , and a 'cont ro l 
monoclonal antibody (HYT 6) of irrelevant 
specifi city (bl. Note the presence oft-PA im-
tnunoreactivity focally (nlTO IPS) in keratino-
cytes w ithin both stra tum spinosu lTI and the 
parakeratotic layer (A alld B) . u-PA immu-
noreactivity is confined to the cy toplasm of 
b?sal keratinocytes (nlTOIUS), in the suprapa-
Pll\ary areas of epidermis (C ami D). Control 
antibody (E) is negative. (Bars = 100 /Llll in 
A, C, and E; 50 /Lm in B and D.) 
With IgG from anti-u-PA clone 6 or clone 12, while the binding 
of anti-li- PA IgG from clone 6 and clone 12 was mutually ex-
clusive. IgG frol11 anti-t-P A clone 3 co uld bind to t-PA together 
Wi th IgG from anti-t-PA clone 1 or 2, whi le anti-t-PA IgG from 
clones 1 and 2 could not bind to t-PA at the same time (Fig IB). 
Therefore, anti-u-PA clone 2 IgG is di rected against an epitope 
which is different from the epitopes against which anti-u-PA clone 
6 and anti- u-PA clone 12 IgGs are directed, while anti-u-PA clone 
6 and anti-u-PA clone 12 mayor m ay no t be directed against the 
sa me epitope. Likewise, anti-t-PA clone 3 is directed aga inst an 
epltope different from the epitope against which anti- t-PA clone 
1 and 3nti-t-PA clone 2 IgGs are directed. Anti-t-PA clone 1 and 
antl-t_p A clone 2 m ayor may not be directed aga inst the same 
epItope. 
Localization of t-P A and u-PA U sin g monoclonal anti-t-PA 
.antlbod ies, all 11 biopsies fro m psoriatic lesions showed cyto-
plaslllic sta ining of keratinocytes present focally within both the 
stratum spinosul11 and the parakeratotic layer (sec Fig 2A and ~Ig 3A,B). Basa l kerat inocytes were consistentl y t-P A ncgative . 
r,ta lI1l1l g of scrial . sections of individual biopsies revealed no. dif-
erenecs 111 the distribution of t-PA Immunoreactivi ty obtall1cd 
With the 3 different m onoclonal antibod ies against t-PA . The m ost 
Intensc sta inin g was secn with IgG from anti-t-PA clone 3. 
T he reactivity pattern of the anti-u-PA ant ibod ics differed 
:1~arkedly from that of anti-t-PA .. Whereas in 1 psoriatic lesion 
I keratlllocytes were u-PA-n cga tIve, thc rema.1lllllg 10 bIOpSies 
C~I1tained u-PA-positivc basal keratinocytes (Figs 2B, 3C,D). Four 
o thesc cases also showcd scattered anti-u-PA-positivc kerati-
1l0cyte clusters in the st ratum spillosul11 . In contrast to t-PA im-
11111no " PA' . . . I reactIVity, u- IlTIlTIunoreactlvlty was never present lilt lC 
parakeratotic ccll s. 
b The u-P A-positive epiderm al ccll types had a restricted distri-
FLttlon, being confined to the supr3pap iUary epidcrm al areas (see 
Igs 2B, 3C,D), i.c., thc areas which usually showcd the most 
pronounced spo ng iosis and/o r exocytosis . The stainin g of serial 
sections of individu31 biopsies with the 3 different monoclona l 
~l1tlbOdics agai nst u-PA resultcd in essentially the sa mc distri-
lIton of sta ined cell s. Use of IgG from ant i-u-PA clone 12 re-
Su ted in the m ost intense staining . 
fi Neither no rm al biopsies nor biopsies from uninvo lvcd skin 
rOnl psoriati c paticnts contain ed u-PA- or t-PA-positive kerat-
;~~cytes, but, similar to previo us findings, all biopsies did show 
[17t Illll11unoreactivity in endothelial cells in dcrmal blood vessels 
v ~II stainin gs with the 3 rn onoclonal control antibodies of in-
°Ev.ed , unin volved, and normal skin were negative (Fig 3E). 
a . ssentJ all y identical resu lts as described for the m o noclonal 
pl~~~bodlcs werc obta incd ~hen . stainin.g of 1 of the biopsies was 
tl 01111 ed With rabbit antibodies agalll st u-PA or t-PA . When 
a leantibody prcparations were absorbed with the correspondin g 
~tlgel1 before immunocytochcmistry and when prciI11mune IgG 
as uscd, no stain in g w as secn (results not shown). 
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DISCUSSION 
The res ults reported above show that keratinocytes in psoriatic 
lesions contain both t-PA and u-PA immunoreactivity, whereas 
keratinocytes in norm al epidermis and uninvolved epidermis from 
pso riati c patients are nega tive for both enzym es, 
The specificity of the staining for the 2 act ivators is strongly 
supported by several findings. First, monoclonal antibodies di-
rected against the same type of activator, but originating from 
different hybridizations and differing with respect to epitopes, 
affinity to the enzym es, and/or ability to inhibit the enzym atic 
activity gave identical localization in the tissue. Second, no cross-
reactivity to closely related proteins (like the other type of plas-
minogen ac tivator and plasminogen) was seen. Third, the staining 
perform ed with monoclonal and po lyclonal antibodies gave iden-
tica l res ults. Fourth, in thc psoriatic lesions , t-PA and u-P A im-
munoreactivity was a property of distinctive keratinocytes, t-P A 
occurrin g in the superficial layers and u-PA occurring preferen-
tiall y in the basal layers. 
The present finding is in agreem ent with our ea rlier finding 
that t-PA, and not u-P A, could be detected in extracts of scales 
from pso riatic patients, usin g immullochemical m ethods [1 6]. 
Thc localiza ti on of t-PA ill the upper keratinocyte layers may 
explain a reported presellce of di-isopropyl f1u o rophosphate-
inhibitable proteolytic activity in the same area [29]. t-PA has 
primari ly been linked with thrombolysis (for revicws, see [1, 4]) 
and has been found in the intact organism in endothelial cells [1 7]. 
We recently reported that t-PA in the intact organism also is 
prescnt in endocrine cells of the rat pituitary [30] and adrenal [31] 
glands. These latte r results, co mbin ed with the present fmding 
of t-PA in the upper keratinocytes in psoriasis, point to t-PA also 
being physio logically involved in proccsscs other than throm-
bolysis . T he possible role of t-PA in psoriasis remains obscure, 
howeve r. 
u-PA has primarily been implicated in tissue degradation oc-
currin g in no rm al and pathologic conditions (for a review, see 
[4]). Examples include involution of mammary glands after the 
termination of lactation [32], in vasio n of trophoblasts into the 
uterus afte r implantation of the fertilized egg [33,34], and cancer 
(35,36]. Thc loca li za ti on of u-PA to the tips of the dermal papillae 
found in thc present study is interestin g in this context, because 
this area is usuall y the site of maximum spongiosis and/or exo-
cytosis in psoriasis and m ay also show tissue degradation and 
abscncc of the basal lamina [37,38]. 
The site of o rigin of the plas minogen activators is not known; 
it appears most likely that thcy are produced by the respective 
keratillocy tes. Hashimoto et al [39] have reported that binding of 
pcmphigus autoantibod y to human epidermal cells results in ele-
vated Icvels of both cell-associated and secreted plasminogen 
activator, M arioka et al [40.] reported th at u-PA expression could 
be induced by wounding of keratinocyte cultures, and Miskin 
and Ben-Ishai [4]] found that UV irrad iation induced u-PA in 
fibroblasts fr0 111 pat ients with xeroderm a pig m entosul11. The na-
32 GR0NDA H L-I-IANSEN ET AL 
ture of the stimu,li that n'lay induce plasminogen activa tors in 
psp ri as is remains to be investigated. 
T he excel/wt lec/l/lical assistaHce oj Maria /w e ChristeHscl/, KariHa Hjort, alld 
K irslc,., LIII,d J akobscl/ is gra tcji, ll y ackl/ owledged. 
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